NCT03572374 Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
| NCT ID | NCT03572374 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 546 participants |
| Start Date | 2019-08-30 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 546 participants in total. It began in 2019-08-30 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is learn more about how being treated for breast cancer affects patients' employment. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs during and after treatment. The app provides advice for patients to use when having conversations about breast cancer with their employers and their doctors. The app is called TEAMWork (Talking to Employers And Medical staff about Work). In this study, the investigators are asking breast cancer patients who are about to receive treatment or who are currently receiving treatment to tell us what aspects of the app work well, so that they can learn how to improve it.
Eligibility Criteria
Inclusion Criteria: Patient Usability Testing Inclusion Criteria: * History of a cancer diagnosis * At least 18 years of age * Male or Female * The ability to give informed consent in English or Spanish * Able to use and read a smartphone (iPhone or Android) * Has a smartphone (iPhone or Android) Community Usability Testing Inclusion Criteria: * At least 18 years of age * Male or Female * The ability to give informed consent in English or Spanish * Able to use and read a smartphone (iPhone or Android) * Has a smartphone (iPhone or Android) Focus Group and Interview Inclusion Criteria: * Completed chemotherapy treatment for stage I-III breast cancer. * Age 18 to 64 (inclusive) * Female * Paid employment (full time or part time) in the three months prior to diagnosis or at time of consent to MSK protocol #10-071 (PI: Blinder) * The ability to give informed consent in English or Spanish * Able to use and read a smartphone (iPhone or Android) * Has a smartphone (iPhone or Android) For Cohort 2: * Participants was covered by Emergency Medicaid at the time of diagnosis and/or at any point during their treatment for breast cancer RCT Inclusion Criteria: * Localized invasive breast cancer (not stage 0 or stage IV) per EMR or breast cancer (not stage 0 or stage IV) per self-report for community participants * If electronic medical record does not specify stage and patient is undergoing (neo)adjuvant chemotherapy, assume stage is I, II or III * Planning to undergo or undergoing adjuvant or neoadjuvant chemotherapy per EMR or planning to undergo or undergo chemotherapy per self-report for community participants * Age 18 to 64 (inclusive) * Female * Employment statue of (full time or part time) (those who are on disability leave/medical leave, and other unique employment circumstances at the PI's dicretion are eligible) * Language preference as English or Spanish * Able to use and read a smartphone or tablet (e.g. iPad, iPhone or Android) * Has access to a smartphone or tablet (e.g. iPad, iPhone or Android) Exclusion Criteria: RCT Exclusion Criteria: * Stage 0 breast cancer (DCIS only) * Stage IV (metastatic) breast cancer * Recurrence with metastases of breast cancer * Participants or family members who are participating in MSK IHCD studies related to social determinants of health
Contact & Investigator
Victoria Blinder, M.D., M.Sc.
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT03572374 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 64 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03572374 currently recruiting?
Yes, NCT03572374 is actively recruiting participants. Contact the research team at blinderv@mskcc.org for enrollment information.
Where is the NCT03572374 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Harrison, United States and 5 additional locations.
Who is sponsoring the NCT03572374 clinical trial?
NCT03572374 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Victoria Blinder, M.D., M.Sc. at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 546 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.